An important milestone for people with secondary progressive MS in Europe
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.
Professor Alan Thompson highlights some of 2016’s research discoveries in MS
Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS